Literature DB >> 2538034

Comparison of six different murine coronavirus JHM variants by monoclonal antibodies against the E2 glycoprotein.

F Taguchi1, J O Fleming.   

Abstract

We have examined six different JHMV variants, sp-4 (recloned wt JHMV), cl-2, CNSV, DL, DS, and JHM-X, in terms of the sizes of the mRNA3 and E2 glycoprotein as well as their reactivity to a panel of monoclonal antibodies to the E2 glycoprotein. Two of these variants, sp-4 and JHM-X, were found to have smaller mRNA3 and E2 glycoprotein species compared with those of the other four variants. In addition, sp-4 and JHM-X were distinguished from the other four variants by their inability to bind to monoclonal antibodies recognizing two antigenic domains of the E2 molecule. Thus, six JHMV variants could clearly be divided into two groups with respect to the size and antigenicity of their E2 glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2538034      PMCID: PMC7131304          DOI: 10.1016/0042-6822(89)90061-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Hybridoma antibodies to the murine coronavirus JHM: characterization of epitopes on the peplomer protein (E2).

Authors:  H Wege; R Dörries; H Wege
Journal:  J Gen Virol       Date:  1984-11       Impact factor: 3.891

2.  Cell-free translation of murine coronavirus RNA.

Authors:  J L Leibowitz; S R Weiss; E Paavola; C W Bond
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

3.  Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence.

Authors:  R G Dalziel; P W Lampert; P J Talbot; M J Buchmeier
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Coronavirus JHM: cell-free synthesis of structural protein p60.

Authors:  S G Siddell; H Wege; A Barthel; V ter Meulen
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

5.  Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: activation of cell-fusing activity of virions by trypsin and separation of two different 90K cleavage fragments.

Authors:  L S Sturman; C S Ricard; K V Holmes
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

6.  Antigenic relationships of murine coronaviruses: analysis using monoclonal antibodies to JHM (MHV-4) virus.

Authors:  J O Fleming; S A Stohlman; R C Harmon; M M Lai; J A Frelinger; L P Weiner
Journal:  Virology       Date:  1983-12       Impact factor: 3.616

7.  Experimental demyelination induced by coronavirus JHM (MHV-4): molecular identification of a viral determinant of paralytic disease.

Authors:  J O Fleming; M D Trousdale; J Bradbury; S A Stohlman; L P Weiner
Journal:  Microb Pathog       Date:  1987-07       Impact factor: 3.738

8.  Coronaviridae.

Authors:  D A Tyrrell; J D Almeida; C H Cunningham; W R Dowdle; M S Hofstad; K McIntosh; M Tajima; L Y Zakstelskaya; B C Easterday; A Kapikian; R W Bingham
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

9.  Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell--cell fusion.

Authors:  A R Collins; R L Knobler; H Powell; M J Buchmeier
Journal:  Virology       Date:  1982-06       Impact factor: 3.616

10.  Characterization of a variant virus isolated from neural cell culture after infection of mouse coronavirus JHMV.

Authors:  F Taguchi; P T Massa; V ter Meulen
Journal:  Virology       Date:  1986-11       Impact factor: 3.616

View more
  34 in total

1.  Mapping of the coronavirus membrane protein domains involved in interaction with the spike protein.

Authors:  C A de Haan; M Smeets; F Vernooij; H Vennema; P J Rottier
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Assembly of the coronavirus envelope: homotypic interactions between the M proteins.

Authors:  C A de Haan; H Vennema; P J Rottier
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype.

Authors:  N Ohtsuka; F Taguchi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein.

Authors:  T M Gallagher; S E Parker; M J Buchmeier
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Topology and membrane anchoring of the coronavirus replication complex: not all hydrophobic domains of nsp3 and nsp6 are membrane spanning.

Authors:  Monique Oostra; Marne C Hagemeijer; Michiel van Gent; Cornelis P J Bekker; Eddie G te Lintelo; Peter J M Rottier; Cornelis A M de Haan
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

6.  Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro.

Authors:  A Lissenberg; M M Vrolijk; A L W van Vliet; M A Langereis; J D F de Groot-Mijnes; P J M Rottier; R J de Groot
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Analysis of the receptor-binding site of murine coronavirus spike protein.

Authors:  H Suzuki; F Taguchi
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virus.

Authors:  S E Parker; T M Gallagher; M J Buchmeier
Journal:  Virology       Date:  1989-12       Impact factor: 3.616

9.  Dynamics of coronavirus replication-transcription complexes.

Authors:  Marne C Hagemeijer; Monique H Verheije; Mustafa Ulasli; Indra A Shaltiël; Lisa A de Vries; Fulvio Reggiori; Peter J M Rottier; Cornelis A M de Haan
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

10.  Induction of self-reactive T cells after murine coronavirus infection.

Authors:  S Kyuwa; K Yamaguchi; Y Toyoda; K Fujiwara
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.